Anti-PD-1 Immunotherapy Shows Superior Outcomes in Gastric Cancer Patients with Chronic Hepatitis B
Key Insights
A retrospective study of 89 gastric cancer (search) patients revealed that those with chronic hepatitis B (search) (CHB) achieved significantly better progression-free survival and overall survival outcomes with anti-PD-1 therapy compared to patients without HBV infection or with resolved hepatitis B.
CHB patients demonstrated median progression-free survival and overall survival that were not reached during the study period, compared to 6-7 months PFS and 15-16 months OS in other patient groups, with hazard ratios indicating 60-70% reduction in disease progression risk.
The enhanced therapeutic response in CHB patients is attributed to alterations in the tumor immune microenvironment caused by chronic viral infection, which may create a more inflamed immunological landscape that potentiates immune checkpoint inhibitor efficacy.
A groundbreaking retrospective study has demonstrated that gastric cancer (search) patients with chronic hepatitis B (search) (CHB) infection achieve significantly superior outcomes when treated with anti-PD-1 immunotherapy compared to patients without HBV infection or those with resolved hepatitis B. The research, conducted at Taizhou Hospital (search) in China, analyzed 89 gastric cancer patients and reveals a paradigm-shifting finding that challenges conventional assumptions about viral infections complicating cancer immunotherapy.
Enhanced Survival Outcomes in CHB Patients
The study stratified patients into three distinct cohorts based on HBV infection status: 13 patients with chronic hepatitis B (search) infection, 49 patients with resolved hepatitis B infection, and 27 patients without evidence of HBV infection. While initial response rates showed no significant differences across groups, with overall response rates of 69.2%, 53.1%, and 51.9% respectively, the survival analyses revealed compelling disparities.
CHB patients demonstrated remarkable progression-free survival benefits, with median PFS not reached during the study period compared to 7 months in HBV-negative patients and 6 months in resolved HBV patients. The hazard ratios indicated a 60-70% reduction in disease progression risk for CHB patients, with statistically significant differences (P = 0.024 for CHB vs. HBV-negative; P = 0.001 for CHB vs. resolved HBV).
Overall survival outcomes similarly favored the CHB cohort, with median OS not reached compared to 15 months and 16 months in HBV-negative and resolved HBV groups respectively. The survival advantage was statistically significant, with hazard ratios of 0.31 and 0.32 for CHB patients compared to the other groups.
Immune Microenvironment Alterations Drive Enhanced Response
The superior outcomes in CHB patients are hypothesized to result from fundamental alterations in the tumor immune microenvironment induced by persistent HBV infection. Chronic viral infections create a state of sustained immune activation and inflammation, leading to a more immunologically active tumor milieu that enhances the efficacy of immune checkpoint inhibitors.
The research suggests that chronic HBV infection upregulates multiple immune checkpoint pathways, including PD-1 (search), TIM-3 (search), CTLA-4 (search), TIGIT (search), and CD244 (search), creating a more immunosuppressive environment. When anti-PD-1 therapy is administered, it effectively reverses the dual inhibition imposed by both the tumor and chronic viral infection, resulting in greater T-cell function recovery compared to patients without chronic viral infection.
Safety Profile Remains Favorable
Importantly, the study demonstrated that anti-PD-1 therapy maintains a favorable safety profile across all patient groups. Among the 89 patients, 75 (84.3%) developed at least one treatment-related adverse event, with common side effects including neutropenia, thrombocytopenia, anemia, hypothyroidism, and hypocortisolism. No grade IV adverse reactions were observed in any group.
Critically, no HBV reactivation events were documented throughout the follow-up period in either CHB or resolved HBV patients. CHB patients showed 19 cases of adverse events with 3 grade III or above, while notably experiencing no cases of immune-mediated hepatitis, compared to 1 case in HBV-negative patients and 3 cases in resolved HBV patients.
Clinical Implications and Future Directions
These findings have profound implications for personalized oncology approaches in gastric cancer (search) treatment. The research suggests that stratifying patients based on HBV status could become essential for treatment selection and prognosis, particularly given the global prevalence of HBV infection and the burden of gastric cancer.
The study challenges the traditional exclusion of HBV-positive patients from immunotherapy trials and supports the safety and efficacy of anti-PD-1 agents in this population. As noted in the research, "anti-PD-(L)1 therapy may be considered for CHB patients with controlled HBV, as evidenced by the favourable safety profile and superior efficacy of this therapy during immunotherapy."
The research team acknowledges several limitations, including the retrospective design, relatively small sample size, and inability to assess PD-L1 (search) expression levels in most patients. Future mechanistic studies will be crucial to delineate the precise immune pathways modulated by HBV in the gastric tumor microenvironment and to identify biomarkers for predicting immune checkpoint inhibitor responsiveness.
This study represents a significant advancement in understanding the complex interplay between viral infections and cancer immunotherapy, potentially opening new avenues for combination approaches that integrate antiviral therapies with immunotherapy to maximize clinical benefit for patients worldwide.